Fig. 5
From: RBM47 is a novel immunotherapeutic target and prognostic biomarker in gliomas
Correlation between RBM47 and inflammation-related metagenes. (A and B) The CGGA and TCGA datasets showed that RBM47 positively correlates with most inflammatory metagenes, except for IgG.
